Key result
Multimodal biological age assessment outperforms single isolated biomarkers for cardiovascular risk evaluation.
Why the study?
Chronological age is an important determinant of cardiovascular risk, but in elderly and senile cardiac patients it does not always reflect the individual rate of aging, functional reserves, and pathophysiological vulnerability of the cardiovascular system.
A multimodal assessment combining geriatric evaluation, laboratory parameters, vascular aging markers, and epigenetic clocks is the most justified approach for evaluating biological age and refining cardiovascular risk in older cardiac patients.
Answers are grounded in this paper and cite their sources.
Biological age may refine CV risk assessment in elderly cardiac patients beyond chronological age; leaves open prospective validation before clinical adoption.
Chronological age remains one of the most important determinants of cardiovascular risk; however, in elderly and senile cardiac patients it does not always reflect the individual rate of aging, functional reserves and pathophysiological vulnerability of the cardiovascular system. Biological age is considered an integrative characteristic of the aging rate formed under the influence of cellular senescence, chronic low-grade inflammation, endothelial dysfunction, mitochondrial impairment, epigenetic drift, arterial stiffness, metabolic disorders and reduced compensatory reserves of the body [1–4, 20–25]. In older cardiac patients, the discrepancy between chronological and biological age has important prognostic significance, as it allows identification of patients with accelerated vascular, metabolic, myocardial and functional aging, refinement of cardiovascular risk, assessment of tolerance to therapy and invasive interventions, and individualization of therapeutic strategy [3, 5–7, 18, 30, 31]. This review systematizes current concepts of the differences between chronological and biological age, considers the pathophysiological mechanisms of accelerated cardiovascular aging, and describes clinicalfunctional, laboratory-phenotypic, epigenetic and instrumental methods for assessing biological age. Special attention is paid to the interpretation of situations in which biological age exceeds chronological age or, conversely, is lower than it. It is shown that the most justified approach is not the isolated use of a single biomarker, but a multimodal assessment combining comprehensive geriatric evaluation, laboratory parameters, markers of vascular aging and, where available, epigenetic clocks [5–8, 28, 29].
No takes yet. Share an insight, caveat, or question.
Волошин et al. (2026) conducted a review in Cardiovascular disease in elderly and senile patients. Multimodal biological age assessment vs. Chronological age or isolated single biomarker assessment was evaluated. Multimodal biological age assessment combining geriatric evaluation, laboratory parameters, vascular markers, and epigenetic clocks is more justified than using an isolated single biomarker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: